Complement inhibition with eculizumab for thrombotic microangiopathy rescues a living-donor kidney transplant in a patient with antiphospholipid antibody syndrome

Transfusion and Apheresis Science

Volumn 56, Issue 3, 2017, Pages 400-403

  Geethakumari, Praveen Ramakrishnan ^a   Mille, Patrick ^a   Gulati, Rakesh ^a   Nagalla, Srikanth ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Antiphospholipid syndrome; Eculizumab; Kidney transplant

Indexed keywords

ACETYLSALICYLIC ACID; BETA2 GLYCOPROTEIN 1 ANTIBODY; BIOLOGICAL MARKER; CARDIOLIPIN ANTIBODY; COMPLEMENT COMPONENT C5; CREATININE; ECULIZUMAB; HEPARIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PHOSPHOLIPID ANTIBODY; WARFARIN; MONOCLONAL ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADULT; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CASE REPORT; COMPLEMENT INHIBITION; CREATININE BLOOD LEVEL; DRUG DOSE TITRATION; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; HEMODIALYSIS; HUMAN; KIDNEY TRANSPLANTATION; LIVING DONOR; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PLASMA EXCHANGE; PLASMAPHERESIS; RENAL GRAFT DYSFUNCTION; SALVAGE THERAPY; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNRELATED DONORS; COMPLICATION; PATHOLOGY; PROCEDURES;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIPHOSPHOLIPID SYNDROME; HUMANS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; THROMBOTIC MICROANGIOPATHIES;

EID: 85017435720     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2017.02.007     Document Type: Article

References (10)

1. Chaturvedi, S., McCrae, K.R., The antiphospholipid syndrome: still an enigma. Hematol Am Soc Hematol Educ Program 2015 (2015), 53–60.
2. Giannakopoulos, B., Krilis, S.A., The pathogenesis of the antiphospholipid syndrome. N Engl J Med 368:March (11) (2013), 1033–1044.
3. González-Moreno, J., Callejas-Rubio, J.L., Ríos-Fernández, R., Ortego-Centeno, N., Antiphospholipid syndrome, antiphospholipid antibodies and solid organ transplantation. Lupus 24:November (13) (2015), 1356–1363.
4. Meroni, P.L., Macor, P., Durigutto, P., De Maso, L., Gerosa, M., Ferraresso, M., et al. Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery. Blood 127:January (3) (2016), 365–367.
5. Hadaya, K., Ferrari-Lacraz, S., Fumeaux, D., Boehlen, F., Toso, C., Moll, S., et al. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant 11:November (11) (2011), 2523–2527.
6. Canaud, G., Kamar, N., Anglicheau, D., Esposito, L., Rabant, M., Noël, L.H., et al. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant 13:August (8) (2013), 2179–2185.
7. Lonze, B.E., Zachary, A.A., Magro, C.M., Desai, N.M., Orandi, B.J., Dagher, N.N., et al. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant 14:February (2) (2014), 459–465.
8. Licht, C., Greenbaum, L.A., Muus, P., Babu, S., Bedrosian, C.L., Cohen, D.J., et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 87:May (5) (2015), 1061–1073, 10.1038/ki.2014.423.
9. Cugno, M., Gualtierotti, R., Possenti, I., Testa, S., Tel, F., Griffini, S., et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost 12:September (9) (2014), 1440–1448.
10. Wehling, C., Kirschfink, M., Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis. J Thromb Haemost 12:September (9) (2014), 1437–1439, 10.1111/jth.12639.